Uncategorized

Replimune gets early August decision date for twice-rejected melanoma drug

Replimune gets early August decision date for twice-rejected melanoma drug

Published

on

Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. The FDA expects to hold an advisory committee meeting in late July.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version